Efficacy and Safety of Chidamide in CBF Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

April 10, 2025

Study Completion Date

December 30, 2027

Conditions

AML

Interventions

DRUG

Cytarabine

Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

DRUG

Chidamide

Chidamide at a dose of 20mg/d twice a week for 3 months.

Trial Locations (1)

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT03031262 - Efficacy and Safety of Chidamide in CBF Leukemia | Biotech Hunter | Biotech Hunter